ORIGINAL ARTICLE

Plasma miR-135a; a potential biomarker for diagnosis of new type 2 diabetes (T2DM)

Mohamad Reza Sarookhani, Maryam Honardoost, Farshad Foroughi, Yousef Khazaei Monfared

Mohamad Reza Sarookhani
Cellular And Molecular Research Center, Qazvin University Of Medical Sciences, Qazvin, Iran

Maryam Honardoost
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran

Farshad Foroughi
Department Of Immunology, School Of Medicin, Qazvin University Of Medical Science, Qazvin, Iran

Yousef Khazaei Monfared
Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, Iran. Email: khazaei_yoosef@outlook.com
Online First: August 05, 2018 | Cite this Article
Sarookhani, M., Honardoost, M., Foroughi, F., Monfared, Y. 2018. Plasma miR-135a; a potential biomarker for diagnosis of new type 2 diabetes (T2DM). Bali Medical Journal 7(2): 296-301. DOI:10.15562/bmj.v7i2.880


Background: MicroRNAs are a class of negative regulators of gene expression. Evidence indicates that miRNAs involved in the pathogenesis of New type 2 diabetes(NT2D)  through decrease the expression of the genes secreting insulin and increase expression of insulin secretion suppressing ones, as well as exocytosis, incorporate in New type 2 diabetes. In this study, we evaluated the expression level of miR-135 in plasma sample of those prone to susceptible diabetes and New type 2 diabetes patients compared to the control group.

Methods:  Subsequently to evaluation of biochemical parameters such as (TG, TC, HDL, and LDL) in susceptible diabetes, New type 2 diabetes and control group, miR-135a level was measured by qRT-PCR in the plasma samples and results were analyzed by  Stata and REST software.

Results: We identified a significant increase in miR-135a expression in New type 2 diabetes and susceptible diabetes samples compared to the control group. AUC in ROC curve analysis was 1.1 respectively (confidence interval of 1.0-1.0) for NT2D and susceptible diabetes group, the best cut-off points for diagnostics in diabetics and susceptible diabetes were 2.00 and 1.02. The optimum sensitivity and specificity for both groups were 100 and 100. Results confirmed the test for 100% confidence in healthy, susceptible diabetes and New type 2 diabetes subjects.

Conclusion: It seems that plasma level of miR-135a can be a desirable biomarker to differentiate T2DM diabetics from the control group.

References

Association AD. Diagnosis and classification of diabetes mellitus. Diabetes care. 2014;37(Supplement 1):S81-S90.

Tuomi T. Type 1 and type 2 diabetes. Diabetes. 2005;54(suppl 2):S40-S5.

Kioumourtzoglou M-A, Rotem RS, Seals RM, Gredal O, Hansen J, Weisskopf MG. Diabetes Mellitus, Obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA neurology. 2015;72(8):905-11.

Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. The Lancet. 2012;379(9833):2300-11.

Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nature Reviews Genetics. 2014;15(1):7-21.

Jin X-F, Wu N, Wang L, Li J. Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cellular and molecular neurobiology. 2013;33(5):601-13.

Honardoost M, Arefian E, Soleimani M, Soudi S, Sarookhani MR. Development of insulin resistance through induction of miRNA-135 in C2C12 cells. Cell Journal (Yakhteh). 2016;18(3):353.

Honardoost M, Soleimani M, Arefian E, reza Sarookhani M. Expression change of miR-214 and miR-135 during muscle differentiation. Cell J (Yakhteh). 2015;17(3).

Abujbara MA, Ajlouni KM. Approach to dysglycemia: Do we need to treat impaired glucose tolerance and impaired fasting glucose? International Journal of Diabetes Mellitus. 2009;1(1):22-5.

Wong L, Lee K, Russell I, Chen C. Endogenous controls for real-time quantitation of miRNA using TaqMan® microRNA assays. Applied Biosystems Application Note. 2007:P11-01.

Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta diabetologica. 2011;48(1):61-9.

Yang Z, Chen H, Si H, Li X, Ding X, Sheng Q, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta diabetologica. 2014;51(5):823-31.

Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, MacDonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432(7014):226-30.

Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ, et al. β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes care. 2014;37(6):1751-8.

Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. Journal of molecular medicine. 2012;90(8):865-75.

Liu Y, Gao G, Yang C, Zhou K, Shen B, Liang H, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. International journal of molecular sciences. 2014;15(6):10567-77.

Rong Y, Bao W, Shan Z, Liu J, Yu X, Xia S, et al. Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PloS one. 2013;8(9):e73272.

Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding J, et al.

MicroRNA‐135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer science. 2014;105(8):956-65.

He F, Peng F, Xia X, Zhao C, Luo Q, Guan W, et al. MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1. Diabetologia. 2014;57(8):1726-36.

Chakraborty C, Doss C, Bandyopadhyay S, Agoramoorthy G. Influence of miRNA in insulin signaling pathway and insulin resistance: micro‐molecules with a major role in type‐2 diabetes. Wiley Interdisciplinary Reviews: RNA. 2014;5(5):697-712.

Agarwal P, Srivastava R, Srivastava AK, Ali S, Datta M. miR-135a targets IRS2 and regulates insulin signaling and glucose uptake in the diabetic gastrocnemius skeletal muscle. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2013;1832(8):1294-303.

Pescador N, Pérez-Barba M, Ibarra JM, Corbatón A, Martínez-Larrad MT, Serrano-Ríos M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PloS one. 2013;8(10):e77251.

Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nature genetics. 2008;40(9):1092-7.

Zhang T, Lv C, Li L, Chen S, Liu S, Wang C, et al. Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. BioMed research international. 2013;2013.

Blondal T, Nielsen SJ, Baker A, Andreasen D, Mouritzen P, Teilum MW, et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59(1):S1-S6.


No Supplementary Material available for this article.
Article Views      : 0
PDF Downloads : 0